Study shows it increases bone formation and bone mass when fed once daily to mice.
- A new study shows that imaging of brain activity with functional near-infrared spectroscopy might offer a more accurate and reliable way to distinguish impairment from cannabis intoxication
- Brain-based testing can be done in the field with small, portable, battery-powered units with the potential to make a meaningful contribution to safety on highways and in the workplace.
Jodi Gilman, PhD,
While it requires further study, we believe brain-based testing could provide an objective, practical and much needed solution.
Center for Addiction Medicine, Massachusetts General Hospital
BOSTON – Researchers at Massachusetts General Hospital (MGH) have found a noninvasive brain imaging procedure to be an objective and reliable way to identify individuals whose performance has been impaired by THC, the psychoactive ingredient in cannabis. The technique uses imaging technology known as functional near-infrared spectroscopy (fNIRS) to measure brain activation patterns that correlate to impairment from THC intoxication. As reported in the journal Neuropsychopharmacology, the procedure could have significant implications for improving highway and workplace safety.
The increased use of cannabis through legalization has created the urgent need for a portable brain imaging procedure that can distinguish between impairment and mild intoxication from THC. “Our research represents a novel direction for impairment testing in the field,” says lead author Jodi Gilman, PhD, investigator in the Center for Addiction Medicine, MGH. “Our goal was to determine if cannabis impairment could be detected from activity of the brain on an individual level. This is a critical issue because a ‘breathalyzer’ type of approach will not work for detecting cannabis impairment, which makes it very difficult to objectively assess impairment from THC during a traffic stop.”
THC has been shown in past studies to impair cognitive and psychomotor performance essential to safe driving, a factor thought to at least double the risk of fatal motor vehicle accidents. The challenge for scientists, however, is that the concentration of THC in the body does not correspond well to functional impairment. One reason is that people who use cannabis often can have high levels of THC in the body and not be impaired. Another is that metabolites of THC can remain in the bloodstream for weeks after the last cannabis use, well beyond the period of intoxication. Hence the need for a different method to determine impairment from cannabis intoxication.
In the MGH study, 169 cannabis users underwent fNIRS brain imaging before and after receiving either oral THC or a placebo. Participants who reported intoxication after being given oral THC showed an increased oxygenated hemoglobin concentration (HbO) -- a type of neural activity signature from the prefrontal cortex region of the brain – compared to those who reported low or no intoxication.
“Identification of acute impairment from THC intoxication through portable brain imaging could be a vital tool in the hands of police officers in the field,” explains senior author and principal investigator A. Eden Evins, MD, MPH, founding director of the Center for Addiction Medicine. “The accuracy of this method was confirmed by the fact impairment determined by machine learning models using only information from fNIRS matched self-report and clinical assessment of impairment 76 percent of the time.”
While the study did not specifically assess fNIRS in roadside assessments of impaired driving, it did cite considerable advantages for such an application. These include the feasibility of inexpensive, lightweight, battery-powered fNIRS devices that allow data to either be stored on wearable recording units or transmitted wirelessly to a laptop. Moreover, fNIRS technology could be incorporated into a headband or cap, and thus require minimal set-up time.
“Companies are developing breathalyzer devices that only measure exposure to cannabis but not impairment from cannabis,” says Gilman. “We need a method that won’t penalize medical marijuana users or others with insufficient amounts of cannabis in their system to impair their performance. While it requires further study, we believe brain-based testing could provide an objective, practical and much needed solution.”
Gilman is associate professor of Psychiatry at Harvard Medical School. Evins is the Cox Family Professor of Psychiatry at Harvard Medical School.
The study was funded by the National Institute on Drug Abuse.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of "America’s Best Hospitals."
Related News and Articles
- Press Release
- Dec | 5 | 2022
Healey & AMG Center for ALS announces new drug regimen for testing DNL343 in HEALEY ALS Platform Trial
The HEALEY ALS Platform Trial is adding a new investigational drug, DNL343, to continue to research new treatments for ALS (Amyotrophic Lateral Sclerosis or Lou Gehrig’s disease).
- Press Release
- Oct | 31 | 2022
Artificial Intelligence Approach May Help Identify Melanoma Survivors Who Face A High Risk of Cancer Recurrence
The method may help clinicians determine which patients would likely benefit from aggressive treatment even at early stages of disease.
- Press Release
- Oct | 26 | 2022
Study reveals less severity of Omicron BA.2, with fewer deaths and lower likelihood of hospitalizations and invasive procedures.
- Press Release
- Oct | 19 | 2022
Antibody-Based Therapy Eliminates Circulating Tumor Cells in Mouse Models of Breast and Pancreatic Cancer
Treatment may prevent cancer metastasis, the predominant cause of cancer-related deaths.
- Press Release
- Oct | 13 | 2022
Unlike other mitochondrial diseases, this form leads to hyperactive mitochondria—causing patients to have low body weight despite excessive food intake.